跳转至内容
Merck
CN

主要文件

查看所有文档

SML2156

埃罗替尼 盐酸盐

≥98% (HPLC), EGFR kinase inhibitor, powder

别名:

774 盐酸盐, CP-358, N-(3-乙炔基苯基)-6,7-双(2-甲氧基乙氧基)喹唑啉-4-胺, OSI-744 盐酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C22H23N3O4 · HCl
化学文摘社编号:
183319-69-9
分子量:
429.90
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD07781272
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

埃罗替尼 盐酸盐, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

Cl.N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC

InChI

1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

InChI key

GTTBEUCJPZQMDZ-UHFFFAOYSA-N

General description

盐酸厄洛替尼是一种抗肿瘤药物。它调节雷帕霉素（mTOR）抑制的机制靶点、表皮生长因子受体下调和表皮间质转化（EMT）抑制。

Application

盐酸厄洛替尼已被用于激活人 PANC-1 胰腺癌细胞系中的线粒体片段化。

Biochem/physiol Actions

盐酸埃罗替尼是受体酪氨酸激酶 EGFR（表皮生长因子受体）的抑制剂。它在临床上用于治疗非小细胞肺癌（NSCLC）和联合治疗转移性胰腺癌。
EGFR 激酶抑制剂；抗肿瘤

Still not finding the right product?

Explore all of our products under 埃罗替尼 盐酸盐

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Kandasamy Saravanakumar et al.
Carbohydrate polymers, 245, 116407-116407 (2020-07-29)
The present work was developed the pH dependent-aptamer AS1411 (APT) decorated and erlotinib (En) loaded chitosan nanoparticles (CSNPs) for promising non-small-cell lung carcinoma (NSCLC) treatment. The characterization studies revealed that formulated APT-En-CSNPs were spherical in shape with size of 165.95
Rabea Oberthür et al.
Cancer letters, 407, 93-105 (2017-08-22)
Overexpression and activation of receptor tyrosine kinases (RTKs), such as the insulin-like growth factor 1 receptor (IGF1R) and the epidermal growth factor receptor (EGFR), are frequent phenomena in colorectal cancer (CRC). Here, we evaluated the effect and the cellular mechanisms
J D Moyer et al.
Cancer research, 57(21), 4838-4848 (1997-11-14)
The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype. CP-358,774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR
查看所有相关文献

全球贸易项目编号

货号GTIN
SML2156-50MG04061835502974
SML2156-100MG04061835502981